Fusion protein from feline leukaemia virus gp70 as vaccine
CA 2113437 A1 · Owner: University Court Of The University Of Glasgow (The) · Inventors: Spibey, Norman; Jarrett, James O.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A vaccine against feline leukaemia virus (FeLV) comprises a protein formed of two proteins derived from FeLV gp70 which are not adjacent in the native protein, particularly VR1 and VR5 or effective fragments thereof. VR5 is preferably attached to the carboxy terminus of VR1. A co-protein such as GST or .beta.-galactosidase may be attached to the amino terminus of the fused protein such, as to stabilise and solubilise the fused protein. Attachments to the carboxy terminus may reduce the immunogenicity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 14, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 14, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 14, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.